Guardion Health Sciences, Inc. GHSI
We take great care to ensure that the data presented and summarized in this overview for Guardion Health Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GHSI
Top Purchases
Top Sells
About GHSI
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
Insider Transactions at GHSI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 26
2024
|
Bradley Louis Radoff > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,054
-40.06%
|
$130,702
$13.8 P/Share
|
Aug 26
2024
|
Bradley Louis Radoff > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
105,486
-19.33%
|
$1,476,804
$14.59 P/Share
|
Jan 10
2023
|
Bradley Louis Radoff > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
31,900
+7.04%
|
$223,300
$7.66 P/Share
|
Jan 09
2023
|
Bradley Louis Radoff > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
84,821
+19.0%
|
$508,926
$6.99 P/Share
|
Jan 06
2022
|
Bret Scholtes CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
37,175
-11.19%
|
$0
$0.65 P/Share
|
Aug 31
2021
|
Bret Scholtes CEO and President |
BUY
Open market or private purchase
|
Direct |
5,500
+2.97%
|
$5,500
$1.23 P/Share
|
Aug 30
2021
|
Bret Scholtes CEO and President |
BUY
Open market or private purchase
|
Direct |
4,500
+2.52%
|
$4,500
$1.26 P/Share
|
Aug 30
2021
|
Donald A Gagliano Director |
BUY
Open market or private purchase
|
Direct |
5,000
+15.27%
|
$5,000
$1.25 P/Share
|
Aug 20
2021
|
Robert N Weingarten Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+7.77%
|
$10,000
$1.14 P/Share
|
Jan 06
2021
|
Bret Scholtes CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
1,068,694
+31.82%
|
-
|
Last 12 Months Summary
Open market or private sale | 116K shares |
---|